Kaci Weaver
Acute Care · Birmingham, ALNPI 1740670280
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (54.9%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by Pharmacosmos Therapeutics Inc. at 46.7% of the total. Reporting peaked in 2022 at $5,403 and has fallen 65.0% since, to $1,889 in 2025. Among acute care clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 320 payments — averaging $34.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pharmacosmos Therapeutics Inc.$5K
- Novo Nordisk$749
- Pfizer$703
- Lilly USA, LLC$643
- AstraZeneca$623
- Sumitomo Pharma America, Inc.$467
- plus $3K from 25 others
What the payments were for
- Speaking & faculty fees$2,48522%
- Travel & lodging$2,40122%
- Food & beverage$6,07655%
- Education$1001%
- Entertainment$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pharmacosmos Therapeutics Inc. | 17 | $5,170 |
| Novo Nordisk | 47 | $749 |
| Pfizer | 43 | $703 |
| Lilly USA, LLC | 37 | $643 |
| AstraZeneca | 27 | $623 |
| Sumitomo Pharma America, Inc. | 22 | $467 |
| Bayer | 19 | $421 |
| AbbVie | 25 | $403 |
| GSK | 8 | $255 |
| Astellas Pharma US Inc | 6 | $225 |
| Amgen(2 entities) | 11 | $211 |
| Otsuka America Pharmaceutical, Inc. | 8 | $192 |
| Teva Pharmaceuticals USA, Inc. | 8 | $173 |
| Boehringer Ingelheim | 7 | $132 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $124 |
| Dexcom, Inc. | 4 | $95 |
| Intuitive Surgical | 1 | $93 |
| Shield Therapeutics Inc | 3 | $61 |
| Xeris Pharmaceuticals, Inc. | 3 | $58 |
| Morphosys, US Inc. | 3 | $41 |
| Phathom Pharmaceuticals, Inc. | 1 | $36 |
| Exact Sciences | 2 | $34 |
| Lundbeck LLC | 2 | $31 |
| Edwards Lifesciences | 1 | $23 |
| Antares Pharma, Inc. | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $17 |
| Paratek Pharmaceuticals, Inc. | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Optos, Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Monoferric$4,844
- AREXVY$140
- TAGRISSO$119
- Stivarga$102
- Vitrakvi$102
How this compares
$11,075 in reported general payments places this provider in the 95th percentile of 711 acute care providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 148 | $165,685 |
| MounjaroTirzepatide | 72 | $96,934 |
| EliquisApixaban | 65 | $59,465 |
| FarxigaDapagliflozin Propanediol | 35 | $35,433 |
| JardianceEmpagliflozin | 36 | $31,791 |
| RybelsusSemaglutide | 26 | $28,648 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 40 | $27,790 |
| MyrbetriqMirabegron | 33 | $20,599 |
| GemtesaVibegron | 19 | $14,865 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $13,186 |
| EntrestoSacubitril/Valsartan | 11 | $11,280 |
| LivaloPitavastatin Calcium | 13 | $10,676 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 18 | $5,300 |
| Vilazodone Hcl | 32 | $4,113 |
| SymbicortBudesonide/Formoterol Fumarate | 12 | $4,073 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $749 | $194,333174 claims |
| Lilly USA, LLCMounjaro | $643 | $96,93472 claims |
| PfizerEliquis | $703 | $59,46565 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $623 | $52,69262 claims |
| Boehringer IngelheimJardiance | $132 | $31,79136 claims |
| GSKTrelegy Ellipta | $255 | $27,79040 claims |
| Astellas Pharma US IncMyrbetriq | $225 | $20,59933 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $467 | $14,86519 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $14 | $10,67613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 711 acute care providers in Alabama.
Other acute care in Birmingham
- Coretta CollinsBirmingham$77K
- Cameron StephensonBirmingham$13K
- Jonathan McCraryBirmingham$13K
- Michelle PriceBirmingham$13K
- Melissa FrenchBirmingham$13K
- Jaime CannonBirmingham$12K
- Alexandra GlennBirmingham$11K
- Bridget CrainBirmingham$10K
- Rachel CookBirmingham$10K
- Kaitlyn JonesBirmingham$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.